FR2811682A3 - Utilisation du dextran marque pour la detection de la permeabilisation de la membrane plasmique ou la mort cellulaire - Google Patents

Utilisation du dextran marque pour la detection de la permeabilisation de la membrane plasmique ou la mort cellulaire

Info

Publication number
FR2811682A3
FR2811682A3 FR0009235A FR0009235A FR2811682A3 FR 2811682 A3 FR2811682 A3 FR 2811682A3 FR 0009235 A FR0009235 A FR 0009235A FR 0009235 A FR0009235 A FR 0009235A FR 2811682 A3 FR2811682 A3 FR 2811682A3
Authority
FR
France
Prior art keywords
dextran
cell
apoptosis
labeled dextran
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0009235A
Other languages
English (en)
Other versions
FR2811682B3 (fr
Inventor
Mohamed Moumaris
Nisen Abuaf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Priority to FR0009235A priority Critical patent/FR2811682B3/fr
Publication of FR2811682A3 publication Critical patent/FR2811682A3/fr
Application granted granted Critical
Publication of FR2811682B3 publication Critical patent/FR2811682B3/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Utilisation du dextran marqu e pour la d etection de la perm eabilisation de la membrane plasmique ou la mort cellulaire. L'invention concerne le dextran, mol ecule disponible dans des poids mol eculaires diff erents, permettant d'analyser le degr e de la perm eabilit e cellulaire. Le dextran coupl e à un fluorochrome, enzymomarqu e ou radiomarqu e est utilis e pour le diagnostic et la d etection des cellules mortes. Le dextran marqu e est particulièrement destin e à suivre l' evolution des diff erents stades de l'apoptose et l' etendue des cellules en n ecrose; rencontr es dans divers situations comme l'inflammation, le cancer, les maladies infectieuses, le d eveloppement embryonnaire, la r egulation du système immunitaire et nerveux, la toxicit e cellulaire, le renouvellement tissulaire physiologique et le vieillissement cellulaire. Dans les techniques in-vitro le dextran marqu e permet d' evaluer le pourcentage de cellules mortes.
FR0009235A 2000-07-13 2000-07-13 Utilisation du dextran marque pour la detection de la permeabilisation de la membrane plasmique ou la mort cellulaire Expired - Fee Related FR2811682B3 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0009235A FR2811682B3 (fr) 2000-07-13 2000-07-13 Utilisation du dextran marque pour la detection de la permeabilisation de la membrane plasmique ou la mort cellulaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0009235A FR2811682B3 (fr) 2000-07-13 2000-07-13 Utilisation du dextran marque pour la detection de la permeabilisation de la membrane plasmique ou la mort cellulaire

Publications (2)

Publication Number Publication Date
FR2811682A3 true FR2811682A3 (fr) 2002-01-18
FR2811682B3 FR2811682B3 (fr) 2003-04-11

Family

ID=8852497

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0009235A Expired - Fee Related FR2811682B3 (fr) 2000-07-13 2000-07-13 Utilisation du dextran marque pour la detection de la permeabilisation de la membrane plasmique ou la mort cellulaire

Country Status (1)

Country Link
FR (1) FR2811682B3 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010073014A1 (fr) * 2008-12-24 2010-07-01 Immunosolv Limited Technique de séparation de cellules
US9804153B2 (en) 2012-08-29 2017-10-31 Inguran, Llc Magnetic removal or identification of damaged or compromised cells or cellular structures
US10379026B2 (en) 2012-08-29 2019-08-13 Inguran, Llc Cell processing using magnetic particles

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010073014A1 (fr) * 2008-12-24 2010-07-01 Immunosolv Limited Technique de séparation de cellules
CN102333860A (zh) * 2008-12-24 2012-01-25 易优诺生物科技有限责任公司 细胞分离技术
US9804153B2 (en) 2012-08-29 2017-10-31 Inguran, Llc Magnetic removal or identification of damaged or compromised cells or cellular structures
US10324086B2 (en) 2012-08-29 2019-06-18 Inguran, Llc Magnetic removal or identification of damaged or compromised cells or cellular structures
US10379026B2 (en) 2012-08-29 2019-08-13 Inguran, Llc Cell processing using magnetic particles
US11531026B2 (en) 2012-08-29 2022-12-20 Inguran, Llc Magnetic removal or identification of damaged or compromised cells or cellular structures
US11630108B2 (en) 2012-08-29 2023-04-18 Inguran, Llc Cell processing using magnetic particles
US11662344B2 (en) 2012-08-29 2023-05-30 Inguran, Llc Magnetic removal or identification of damaged or compromised cells or cellular structures
US12332239B2 (en) 2012-08-29 2025-06-17 Inguran, Llc Magnetic removal or identification of damaged or compromised cells or cellular structures

Also Published As

Publication number Publication date
FR2811682B3 (fr) 2003-04-11

Similar Documents

Publication Publication Date Title
Vanhoof et al. Distribution of proline-specific aminopeptidases in human tissues and body fluids
DE60038993D1 (de) Oligonukleotidprimer zur reversen Transkription für den effizienten Nachweis von HIV-1 und HIV-2 und Methoden ihrer Verwendung
EA200100819A1 (ru) Способ получения мембранных пузырьков
AR027346A1 (es) Tira de analisis reactiva para la determinacion de analitos
EP1085314A3 (fr) Analyseur de gaz
Dunston et al. Vitiligo is associated with HLA-DR4 in black patients: a preliminary report
EP1381864A4 (fr) Detection du candida
ATE318930T1 (de) Nukleinsäuresonden zur detektion von candida- spezies
ES2103582T3 (es) Ensayo y kit.
FR2811682A3 (fr) Utilisation du dextran marque pour la detection de la permeabilisation de la membrane plasmique ou la mort cellulaire
AR004826A1 (es) Metodo para identificar a un paciente en riesgo de adquirir una afeccion trombotica debido a la deficiencia de factor v y un equipo de diagnostico para realizar dicho metodo.
Anderson et al. Salivary protein polymorphisms in caries-free and caries-active adults
ATE404866T1 (de) System und verfahren zur in-vitro-analyse von therapeutischen wirkstoffen
ES2172287T4 (es) Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa.
CA2317816A1 (fr) Procede de detection de peptides
SE9403833D0 (sv) Analysförfarande och kit
ATE239918T1 (de) Verfahren zur im-vitro-analyse von toxischen und allergenen substanzen
DE69822149D1 (de) Erkennung von tmorspezifische genprodukte
KR20210139351A (ko) 치주병 원인균의 검출 방법
AU2003286039A1 (en) Biosensors, and method and kits for using same
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
JP6638648B2 (ja) 生体試料中の亜鉛測定試薬及び測定方法
Weinstein et al. Lactate dehydrogenase isoenzymes in human saliva
RU2005101339A (ru) Способ для определения уровня эндотоксина в растворе гемоглобина
RU97108123A (ru) Способ выявления "группы опухолевого риска" и скрининга ранних стадий опухолевых заболеваний

Legal Events

Date Code Title Description
ST Notification of lapse
RN Application for restoration
FC Favourable decision of inpi director general on an application for restauration.
ST Notification of lapse